Analyst firms · BTIG · MLTX
BTIG MLTX price target and rating history
MoonLake Immunotherapeutics (MLTX) · Health Care
BTIG rates MoonLake Immunotherapeutics (MLTX) Buy with a $24 price target, as of its latest action on Jan 9, 2026. It has published 3 rating actions on MLTX since March 2023, including 1 upgrade and 1 downgrade. Across 5 firms with a MLTX price target in the last 12 months, the median target is $24. BTIG's target matches it.
- Current rating
- Buy
- Price target
- $24
- Median target, all firms
- $24
- Actions on MLTX
- 3
BTIG price target on MLTX
Every BTIG rating on MLTX
- Jan 9, 2026
- Sep 29, 2025DowngradeBTIG downgrades to Neutral from Buy
- Mar 9, 2023
How other firms rate MLTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $57 | Nov 6, 2026 |
| Wolfe Research | Outperform | $24 | Mar 23, 2026 |
| Rothschild & Co Redburn | Buy | $40 | Mar 19, 2026 |
| Goldman Sachs | Sell | $10 | Jan 15, 2026 |
| BTIG | Buy | $24 | Jan 9, 2026 |
Questions about BTIG and MLTX
- What is BTIG's price target for MLTX?
- BTIG's latest stated price target for MoonLake Immunotherapeutics (MLTX) is $24, from its action on Jan 9, 2026.
- What is BTIG's rating on MLTX?
- BTIG rates MLTX Buy, a bullish rating, as of Jan 9, 2026.
- When did BTIG last change its view on MLTX?
- On Jan 9, 2026, BTIG upgrades to Buy from Neutral, price target $24.
- How does BTIG's MLTX target compare with other analysts?
- Across 5 firms with a MLTX price target in the last 12 months, the median target is $24. BTIG's target matches it.
More MLTX rating histories
All BTIG ratingsMLTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.